Last reviewed · How we verify
NCT03310905
Abdominal Wall Transplant
NA trial testing Abdominal Wall Transplant with another solid organ transplant in Transplant;Failure,Kidney in 5 participants. Currently enrolling.
1 January 2028
Quick facts
| Lead sponsor | Duke University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 1 May 2018 |
| Primary completion | 1 January 2028 |
| Estimated completion | 1 June 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Abdominal Wall Transplant with another solid organ transplant
- Abdominal Wall Transplant alone
Conditions studied
- Transplant;Failure,Kidney — all drugs for Transplant;Failure,Kidney →
- Transplant; Failure, Liver — all drugs for Transplant; Failure, Liver →
- Transplant; Failure, Bowel — all drugs for Transplant; Failure, Bowel →
- Abdominal Wall Defect — all drugs for Abdominal Wall Defect →
Sponsor
Duke University
Who can join
Adults 18 to 65, any sex, with Transplant;Failure,Kidney or Transplant; Failure, Liver. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this protocol is to determine the safety and efficacy of abdominal wall transplantation as a treatment for the reconstruction of abdominal wall defects. Abdominal wall transplantation may be performed alone or in combination with another transplant.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03310905
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transplant;Failure,Kidney
Currently open trials in the same condition.
- NCT05613010 — Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant · NA · recruiting
- NCT05449496 — Dietary Intervention to Improve Kidney Transplant Outcomes · NA · active not recruiting
- NCT03737604 — TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant · Phase 4 · recruiting
- NCT03380962 — Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant · Phase 1, PHASE2 · active not recruiting
Other Duke University trials
Trials by the same sponsor.
- NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation · NA · not yet recruiting
- NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment · NA · not yet recruiting
- NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
- NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · NA · not yet recruiting
- NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03310905 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Duke University
- Last refreshed: 7 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03310905.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing